Global X Genomics & Biotechnology ETF
Price through Oct 6, 2026 · Flows through Aug 23, 2024. Figures use the latest available records, not a live quote. Fund details retrieved Oct 6, 2026. Holdings snapshot retrieved Oct 6, 2026.
The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies that are positioned to benefit from further advances in the field of genomic science and biotechnology, as well as applications thereof (collectively, "Genomics & Biotechnology Companies"), as defined by Solactive AG, the provider of the underlying index. The fund is non-diversified.
SOURCE: MARKET TAPE & DAILY CREATION/REDEMPTION RECORDS · 3Y SHOWN · NET −$93M OVER THIS RANGE
Recent fund-flow records are unavailable, while the price has returned +48.7% so far this year. At 0.50% a year it is not the cheapest way in — IWM has a reported fee of 0.19%.
COMPOSED FROM THE FUND’S OWN DAILY RECORDS · UPDATED WITH EACH REFRESH
CELL SIZE IS PORTFOLIO WEIGHT · COLOR IS THE CHANGE IN THE LATEST AVAILABLE SNAPSHOT · TOP 40 POSITIONS
| # | Holding | Weight | Price | Day | 52-wk | |
|---|---|---|---|---|---|---|
| 1 | MRNAMODERNA | 9.72% | $187.46 | -7.8% | ||
| 2 | TWSTTWIST BIOSCIENCE | 8.37% | $166.97 | -18.6% | ||
| 3 | TXG10X GENOMICS | 7.68% | $80.66 | -17.5% | ||
| 4 | ILMNILLUMINA | 5.99% | $273.54 | -6.9% | ||
| 5 | NTRANATERA | 5.45% | $400.65 | -5.9% | ||
| 6 | GHGUARDANT HEALTH | 5.56% | $170.69 | -8.8% | ||
| 7 | TECHBIO-TECHNE | 3.29% | $72.43 | -0.2% | ||
| 8 | VRTXVERTEX PHARMACEUTICALS | 3.06% | $502.31 | -0.2% | ||
| 9 | QGENQIAGEN NV | 3.05% | $45.65 | -0.3% | ||
| 10 | BMRNBIOMARIN PHARMACEUTICAL | 2.83% | $56.22 | -2.3% | ||
| 11 | CRSPCRISPR THERAPEUTICS AG | 2.70% | $54.00 | -5.8% | ||
| 12 | VCYTVERACYTE | 2.58% | $44.65 | -6.3% | ||
| 13 | BNTXBIONTECH SE | 2.39% | $95.73 | -2.0% | ||
| 14 | CAICaris Life Sciences | 2.54% | $27.45 | -9.7% | ||
| 15 | ARWRARROWHEAD PHARMACEUTICALS | 2.24% | $61.54 | -1.3% |
The full book, free with one sign-in.
Top 15 positions are open to everyone. Sign in once and every fund’s complete holdings — plus CSV export, watchlists, and flow alerts — unlock across the network.
Sign in to see all 41| 1 week | -4.1% |
| 1 month | +5.2% |
| 3 months | +14.9% |
| 6 months | +53.0% |
| YTD | +48.7% |
| 1 year | +64.6% |
| 3 years | — |
PRICE RETURN, DISTRIBUTIONS NOT REINVESTED
| 1 week | — |
| 1 month | — |
| 3 months | — |
| YTD | — |
| 1 year | — |
CREATION/REDEMPTION DOLLARS, DAILY RECORDS
The top holding is 9.7% of the book; the top ten carry 57%. Spread across 51+ names, it behaves like roughly 22 equally-weighted positions.
VOLATILITY & DRAWDOWN FROM THE DAILY TAPE · CONCENTRATION FROM THE LATEST DISCLOSED BOOK
| Most-traded holdings, options premium | Bullish | Bearish |
|---|---|---|
| MRNA MODERNA | $52M | $54M |
| LLY ELI LILLY | $48M | $46M |
| TWST TWIST BIOSCIENCE | $8M | $10M |
| ILMN ILLUMINA | $4M | $6M |
| NTRA NATERA | $3M | $3M |
TODAY’S OPTIONS PREMIUM IN THE FUND’S UNDERLYING NAMES
Due diligence cuts both ways. These funds sit on the same shelf and beat GNOM on at least one dimension that matters — the fee, the asset base, or where the money is going.
| Fund | Fee | Assets | Flow, 1M | The case | |
|---|---|---|---|---|---|
| IVV iShares Core S&P 500 ETF | 0.03% | $896.9B | +$21.7B | -47bp on fee · 10593× the assets · +$21.7B in over the month | Head-to-head |
| SPDW State Street SPDR Portfolio Developed World ex-US ETF | 0.03% | $41B | +$286M | -47bp on fee · 485× the assets · +$286M in over the month | Head-to-head |
| BBUS JPMorgan BetaBuilders U.S. Equity ETF | 0.02% | $9.6B | +$187M | -48bp on fee · 113× the assets · +$187M in over the month | Head-to-head |
| SPMD State Street SPDR Portfolio S&P 400 Mid Cap ETF | 0.03% | $18.4B | +$199M | -47bp on fee · 217× the assets · +$199M in over the month | Head-to-head |
| SPYG State Street SPDR Portfolio S&P 500 Growth ETF | 0.04% | $57.9B | +$717M | -46bp on fee · 683× the assets · +$717M in over the month | Head-to-head |